Cryoport, Inc. (CYRX): Shareholders' Equity
$502.64M
As of 2025-12-31
$490.70M
As of 2026-06-30
-3.3%
3-year compound annual growth
+5.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $502.64M | +25.1% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $401.90M | -17.8% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $489.02M | -12.0% | 2026-03-05, Balance as of period end |
| 2022-12-31 | $555.84M | -13.4% | 2025-03-07, Balance as of period end |
| 2021-12-31 | $641.83M | +67.7% | 2024-03-13, Balance as of period end |
| 2020-12-31 | $382.70M | +203.1% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $126.28M | +227.6% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $38.55M | +115.5% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $17.89M | +214.9% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $5.68M | n/a | 2018-03-08, Balance as of period end |
| 2016-03-31 | $3.10M | n/m | 2018-03-08, Balance as of period end |
| 2015-03-31 | -$416.3K | n/m | 2016-06-28, Balance as of period end |
| 2014-03-31 | -$2.30M | n/m | 2015-05-19, Balance as of period end |
| 2013-03-31 | -$2.06M | n/m | 2014-06-25, Balance as of period end |
| 2012-03-31 | $3.73M | -37.3% | 2013-06-25, Balance as of period end |
| 2011-03-31 | $5.95M | n/a | 2012-06-27, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | 2025-12-31 | $502.64M | +25.1% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$438.17M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $33.59M | -3.0% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $352.46M | +53.9% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $212.38M | -34.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
| Liquidia Corp (LQDA) | 2025-12-31 | $44.75M | -43.6% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $14.33M | n/m |
Compare CYRX, PHAT, SNDX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗